Drug intelligence / Profile preview

SPH-103

Development stage: Preclinical
Lead developer: Sapphire Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SPH-103 is an orally administered drug candidate being developed by Sapphire Therapeutics for the treatment of celiac disease. It is designed to target a novel, undisclosed receptor that modulates the NFkB and IL-22 pathways, which are critical regulators of intestinal inflammation and mucosal homeostasis. Unlike many current therapeutic approaches for autoimmune and inflammatory conditions, SPH-103 aims to provide a non-immunosuppressive treatment option. As of early 2024, the program is in the lead identification stage of preclinical development.

Beyond the preview

Go deeper on SPH-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH-103.

Explore the full profile